Fig. 6. The combination of Alisertib and Sorafenib is a promising therapeutic approach for advanced TC in vivo.

A Representative images of subcutaneous xenografts in NSG mice injected 8305 C cells treated with Alisertib (30 mg/kg), Sorafenib (30 mg/kg) or both drugs. n = 5 mice per group. The subcutaneous xenografts were dissected on day 13. B, C Tumor volumes were measured with tumor weights (B) and growth curves (C) in each group. D The expression levels of Ki67 and p-Aurora-A in xenografts of each group were assessed by immunohistochemical staining. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control group. ^#P < 0.05, ^##P < 0.01, ^###P < 0.001, compared with the combination group. The data are presented as the mean ± SD.